An investigation into the relationship between disease-free survival and FDX1 expression in sarcoma patients showed that those with low FDX1 expression experienced a longer disease-free survival than those with high FDX1 expression, as illustrated in Fig. S4B. To conclude the cuproptosis, the expression of FDX1 in tumor tissues from the different groups was assessed through Western blotting. This evidence concerns the gene FDX1 and sarcoma.